

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Trab 1



Section 1. Identifying Inform	ation	
Given Name (First Name)  Trine	2. Surname (Last Name) Trab	3. Date 05-February-2020
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Svend Eggert Jensen
5. Manuscript Title Koronar forkalkning hos patienter diagr	nosticerede med skizofren	i
6. Manuscript Identifying Number (if you kn UFL-11-19-0623	ow it)	
Section 2. The Work Under Co	onsideration for Public	cation
	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
If yes, please fill out the appropriate info Excess rows can be removed by pressing		ve more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant	n-Financial other? Comments
The Lundbeck Foundation	<b>✓</b>	
Section 3. Relevant financial	activities outside the	submitted work.
of compensation) with entities as descri	bed in the instructions. Use port relationships that we	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re <b>present during the 36 months prior to publication</b> .
Section 4. Intellectual Proper		
Intellectual Proper	ty Patents & Copyri	ghts
Do you have any patents, whether plant	ned, pending or issued, bı	roadly relevant to the work? Yes No

Trab 2



Relationships not covered above
relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
wing relationships/conditions/circumstances are present (explain below):
ationships/conditions/circumstances that present a potential conflict of interest
anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement Irnals may ask authors to disclose further information about reported relationships.
Disclosure Statement
ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
grants from The Lundbeck Foundation, during the conduct of the study; .

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Trab 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1 Identifying information.

### The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Ernst Nielsen



	Identifying Infor	mation	18 7 15	HONE PA	P 1/42	3/ - S - J#	NO S	
1. Given Name ( René	RESPUEDO SATALO	ACTION IN	ne (Last Name) Isen			3. Date 03-Februar	ry-2020	
4. Are you the co	orresponding author?	Yes	<b>√</b> No		ding Author's N gert Jensen	ame		
5. Manuscript Ti Calciumscore o	tle og kardiovaskulær risiko	ovurdering h	os patienter m	ed skizofreni				
6. Manuscript ld	entifying Number (if you	know it)						
Section 2.	The Work Under	Considerat	ion for Publi	cation	1000	-180 T TO		
Section 3.	Belowetf	1						
THE RESERVE OF THE PERSON NAMED IN	Relevant financia			submitted	work.	- Indiana		re e
of compensation clicking the "Ac Are there any r	the appropriate boxe on) with entities as deso dd +" box. You should r elevant conflicts of inte I out the appropriate in	cribed in the eport relation rest?	instructions. Unships that we les	se one line fo	or each entity;	add as many	lines as you ne	ed by
of compensation clicking the "Ac Are there any re If yes, please fil	on) with entities as desord dd +" box. You should relevant conflicts of inte l out the appropriate in	cribed in the eport relation rest?  Y	instructions. Unships that we les No elow.	se one line fore present d	or each entity; uring the 36	add as many	lines as you ne	ed by
of compensation of compensation of the "Action of t	on) with entities as deso dd +" box. You should r elevant conflicts of inte I out the appropriate in	cribed in the eport relation rest?	instructions. Unships that we les No elow.	se one line fore present d	or each entity; uring the 36	add as many months prio	lines as you ne	ed by
of compensation of compensation of the "Action of t	on) with entities as deso dd +" box. You should r elevant conflicts of inte I out the appropriate in	cribed in the eport relation erest?  Y	instructions. Unships that we les No elow.	se one line fore present d	or each entity; uring the 36	add as many months prio	lines as you ne	ed by
of compensation of compensation of the "Action of t	on) with entities as deso dd +" box. You should r elevant conflicts of inte I out the appropriate in	cribed in the eport relation erest?  Y	instructions. Unships that we les No elow.  Personal No Fees S	se one line fore present d	or each entity; uring the 36	add as many months prio	lines as you ne	ed by
of compensation of compensation of the "Ac Are there any refere there any refere the properties of the compensation of the "Ac Are there any refere the compensation of the compensation o	on) with entities as desord +" box. You should relevant conflicts of intell out the appropriate in	cribed in the eport relation erest?  Y	instructions. Unships that we les No elow.  Personal No Fees S	se one line fore present d	or each entity; uring the 36	add as many months prio	lines as you ne	ed by
of compensation clicking the "Ac Are there any r	on) with entities as desord +" box. You should relevant conflicts of intell out the appropriate in ticals	cribed in the eport relation erest?  Y	instructions. Unships that we les No elow.  Personal No Fees?	se one line fore present d	or each entity; uring the 36	add as many months prio	lines as you ne	ed by



Section 4.	Intellectual Property Patents & Copyrights
Do you have an	y patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	owing relationships/conditions/circumstances are present (explain below):
✓ No other rel	ationships/conditions/circumstances that present a potential conflict of interest
	nanuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. urnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the ab below.	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
	n reports grants from Otsuka Pharmaceuticals, personal fees from Eli Lilly , personal fees from Lundbeck nal fees from Teva Pharmaceuticals, from Otsuka Pharmaceuticals, personal fees from Janssen-Cilag, outside work;

#### **Evaluation and Feedback**

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Ernst Nielsen 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Frøkjær 1



Section 1. Identifying Inform	nation		
1. Given Name (First Name) Jens Brøndum	2. Surname (Last Name) Frøkjær	3. Date 03-February-2020	
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Svend Eggert Jensen	
5. Manuscript Title Calciumscore og kardiovaskulær risikov	rurdering hos patienter me	ed skizofreni	
6. Manuscript Identifying Number (if you kr	now it)		
Section 2. The Work Under Co	onsideration for Public	cation	
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) ta monitoring board, study design, manuscript preparation,	for
Section 3. Relevant financial	activities outside the s	submitted work.	
of compensation) with entities as descri	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amouse one line for each entity; add as many lines as you need be present during the 36 months prior to publication.	
Section 4. Intellectual Proper	rty Patents & Copyric	yhts	
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the work? ☐ Yes 📝 No	

Frøkjær 2



nents

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Frøkjær 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Info	mation	A 1 201 A 1 2 20 20 20 A
Given Name (First Name)     Svend Eggert	2. Surname (Last Name) Jensen	3. Date 03-February-2020
4. Are you the corresponding author?	✓ Yes No	
Manuscript Title     Calciumscore og kardiovaskulær risik     Manuscript Identifying Number (if you	ovurdering hos patienter med skizofren know it)	ni
Section 2. The Work Under	Consideration for Publication	
Did you or your institution <b>at any time</b> re any aspect of the submitted work (includi statistical analysis, etc.)? Are there any relevant conflicts of into	ng but not limited to grants, data monitorin	y (government, commercial, private foundation, etc.) for ng board, study design, manuscript preparation,
Section 3. Relevant financia	al activities outside the submitted	work.
of compensation) with entities as des	cribed in the instructions. Use one line f report relationships that were <b>present</b> of	nave financial relationships (regardless of amount for each entity; add as many lines as you need by during the 36 months prior to publication.
Section 4. Intellectual Prop	erty Patents & Copyrights	
BASE   STATES	nned, pending or issued, broadly relev	ant to the work? Yes V No



Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of sencing, what you wrote in the submitted work?
Yes, the follo	owing relationships/conditions/circumstances are present (explain below):
✓ No other rel	ationships/conditions/circumstances that present a potential conflict of interest
	nanuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. urnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the ab below.	pove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Jensen has	nothing to disclose.

### **Evaluation and Feedback**

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.